Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery

• Status: Completed
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems.

Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI > 35 kg/m2). Clinical and research evidence shows that shortly after RYGB, T2DM resolves with improving glucose tolerance. Foregut hypothesis behind bariatric surgeries postulate, that bypassed portions of intestine contain a substance, that acts as an anti-incretin, ie. to counteract metabolically favourable incretins. In view of the recent studies, it may be that GIP is really the anti-incretin behind this hypothesis.

The current study is conducted to investigate the vasoactive roles of the GIP. The investigators aim to show that GIP is the major contributor to the blood flow and tissue blood volume observed in postprandial state.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Turku University Hospital
• Collaborators: Academy of Finland; Lund University; Sigrid Juselius Foundation
• Treatments: Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Incretins

Criteria

Inclusion Criteria:

1. BMI > 35 kg/m2

2. Type 2 diabetes mellitus (fasting glucose more than 7 mmol/l)

3. Age: 18-60 years

4. Previous, carefully planned, conservative treatments for obesity have failed

Exclusion Criteria:

1. BMI over 60 kg/m2

2. Weight more than 170 kg

3. Waist circumference > 150 cm

4. Insulin treatment requiring type 2 diabetes mellitus

5. Mental disorder or poor compliance

6. Eating disorder or excessive use of alcohol

7. Active ulcus-disease

8. Pregnancy

9. Past dose of radiation

10. Presence of any ferromagnetic objects that would make MR imaging contraindicated

11. Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results

Inclusion criteria for the control group

1. BMI 18-27 kg/m2

2. Age 18-60 years

3. Fasting plasma glucose less than 6.1 mmol/l

4. Normal glucose tolerance test (OGTT)

Exclusion criteria for the control group

1. Blood pressure > 140/90 mmHg

2. Any chronic disease

3. Mental disorder or poor compliance

4. Any chronic medical defect or injury which hinder/interfere everyday life

5. Eating disorder or excessive use of alcohol

6. Pregnancy

7. Past dose of radiation

8. Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results

9. Presence of any ferromagnetic objects that would make MR imaging contraindicated

10. Smoking